Logos Global Management LP 89bio, Inc. Transaction History

Logos Global Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$15.06 - $19.41 $4.67 Million - $6.02 Million	310,000 New	310,000 $4.79 Million
Q3 2020 Nov 16, 2020	SELL	$24.34 - $38.82 $7.06 Million - $11.3 Million	-290,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$19.93 - $31.2 $856,990 - $1.34 Million	43,000 Added 17.41%	290,000 $5.78 Million
Q1 2020 May 15, 2020	BUY	$16.4 - $41.77 $2.63 Million - $6.7 Million	160,409 Added 185.25%	247,000 $6.24 Million
Q4 2019 Feb 14, 2020	BUY	$19.75 - $33.44 $1.71 Million - $2.9 Million	86,591 New	86,591 $2.28 Million

163

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $417M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.